Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
Launched by UNIVERSITY OF COLORADO, DENVER · Jul 24, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The I-I-CAPTAIN-HF clinical trial is studying new tools designed to help doctors and patients improve the use of important heart medications for people with heart failure, specifically those whose heart doesn't pump well (known as reduced ejection fraction). The goal is to encourage patients to work with their healthcare providers to make positive changes to their treatment, which can lead to better heart health and quality of life. This trial will test two different tools: one that sends information to patients before their clinic visits and another that provides alerts to doctors during appointments. The study will take place at five health systems across the country.
To participate in this trial, patients need to be over 18 years old, have a specific type of heart failure, and not be on all recommended medications at the right doses. They should have had a cardiology appointment in the last year. Eligible clinicians include doctors and advanced practice providers who regularly care for patients with this type of heart failure. Participants can expect to take part in a study that aims to enhance their treatment options and overall heart health while contributing to research that could help many others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Clinician:
- • Clinician (MD, PA, NP) who practices in cardiology outpatient clinics
- • Regularly sees patients with left ventricular ejection fraction (EF) \</=40%, where their panel of patients over the last year included at least 25 patients with heart failure with reduced ejection fraction (HFrEF)
- Patient:
- • Age \> 18 years
- • LVEF \</=40% on most recent cardiology imaging study
- • Has had a routine cardiology outpatient clinic appointment in the previous 12 months
- • Not on all 4 pillars of GDMT at optimal doses: (1) beta blockers, (2) angiotensin receptor-neprilysin inhibitor/angiotensin converting enzyme inhibitor/angio-tensin receptor blocker, (3) aldosterone receptor antagonists, (4) sodium-glucose co-transporter
- Exclusion Criteria:
- Patient:
- • Has a left ventricular assist device
- • Under evaluation for or listed for transplant (or s/p transplant)
- • Glomerular filtration rate (GFR) less than 15
- • On IV inotropes
- • On hospice care
- • Non-English or Non-Spanish speaking
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Salt Lake City, Utah, United States
Aurora, Colorado, United States
New Haven, Connecticut, United States
Walnut Creek, California, United States
Patients applied
Trial Officials
Larry A Allen, MD, MHS
Principal Investigator
University of Colorado, Denver
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported